



CONFERENCE BROCHURE

Discovery 2024 & Automate 2024

22 - 23 May 2024 | Basel, Switzerland

Bringing together 500+ key experts in the field of drug discovery screening, target identification, validation & neuroscience drug development. Oxford Global's Discovery Europe 2024, features the 22nd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress and the 5th Annual Neuroscience Drug Development Congress. The co-located Automate 2024 featuring 3rd Annual SmartLabs Automation and Robotics Congress stands as the foremost venue to explore cutting-edge advancements in smartlabs automation and mobile robotics.

Key Speakers Include



DAVIDE GIANNI
Senior Director, AstraZeneca



JEFF MESSER
Director Analytics, GSK



THIERRY PRONCE,
Director, Quality &
Digital Strategy for
Analytical R&D, GSK



REKHA LAKSHMANAN,
Global Head Of Data Office,
AstraZeneca



NATHALIE CARTIER-LACAVE
Senior Vice President
Neurobiology, Askbio



STEVEN DRIVER,
Global Energy
Leader,
Sanofi



BIANCA BRENNER, Head of
MES Projects,
Bayer



George Karageorgis,
Senior Scientist,
AstraZeneca



JOHAN LUTHMAN, Executive
Vice President of R&D,
Lundbeck



SANNE GLAD, Scientific
Director, Amgen Research
Copenhagen

Book Now 

More Information:

oxfordglobal.com/discovery/events/discovery-europe-2024
oxfordglobal.com/discovery/events/automate-europe-2024

 @OGConferences

 LinkedIn



WELCOME TO

Discovery Europe 2024 & Automate 2024

Oxford Global is delighted to share with you the 2024 program for our Discovery Europe 2024 & Automate 2024 events in Basel on May 22-23. With an influx of new technologies and innovations in the drug discovery field in recent years, including the promising application of AI/ML in discovery processes and the rapid growth of the smart labs and mobile robotics industry, we are pleased to bring together key opinion leaders to discuss the pressing challenges and future opportunities that are driving the growth of these markets. Our combined program, featuring the 22nd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress, 5th Annual Neuroscience Drug Development Congress, as well as the 3rd Annual Smart Labs Automation & Robotics Congress, offers a full range of cutting-edge presentations and interactive sessions, including panel discussions, workshops, and roundtables pertaining to the latest developments. Don't miss out on attending this 2-day congress and networking with like-minded peers to gain inspiration for advancing your research.

Benefits to Attending

- ✓ **Dive into the future of drug discovery in new modalities** such as targeted protein degradation, RNA based therapeutics and case studies on what makes good novel targets.
- ✓ **The latest updates on the integration of approaches for HIT finding** - DNA-encoded libraries, targeted protein degradation, and covalent inhibitors as valuable tools in hit optimization in drug discovery.
- ✓ **Examine the latest advancements and emerging trends in developing neurological treatments**, including targeted approaches and novel strategies.
- ✓ **Discover collaborative solutions to bridging the gap between automation & digitalisation.** Our event brings together key opinion leaders to discuss building a digital and cost-effective R&D and QC lab; implementation of modelling and paperless labs and data FAIRification & enhancing lab connectivity for streamlined FAIR data capture.
- ✓ **Explore the latest developments in automation with AI/ML and robotics tools in drug discovery & development.** Presentations will cover lab robotics & tools for drug discovery workflows such as microplate readers and automated liquid handlers, AI/ML in the lab and robotic process automation.



Welcome

Attendees

Sponsors

Session
Topic AreasProgramme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationOxford
Global
Plus PassForthcoming
Events

Book Now

Linked

X @OGConferences

Network and Knowledge-Share

500+ VPs, Directors & Senior Managers will be on-site, coming from leading healthcare, biotech, pharma and research institutions in the following fields & more:


- Medicinal Chemistry
 - Chemical Biology
 - Drug Design
 - Drug Discovery
 - Target Discovery
- Process Chemistry
 - Neurotechnology
 - Neuropharmacology
 - Drug Screening
 - Organoid Development
- Lab Automation
 - Lab Digitisation
 - Mobile Robotics
 - HTE
 - AI/ML
- SmartLabs
 - Data Science
 - Digital Twins
 - In Silico Models
 - Workflow Automation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated refreshment (networking) breaks covering:

- Protein Degradation Tools
 - Screening Technologies
 - Library Optimisation
 - Target Validation
 - Neuroengineering Tools
- Neuroinformatic Tools
 - Discovery IT
 - Protein Degradation
 - Assay Development
 - Organoid Discovery
- Robotics Software
 - Workflow Automation
 - Lab Automation
 - Smart Manufacturing
 - Robotic Automation
- Data Management
 - Data Analytics
 - Data Integration
 - Autonomous Mobile Robots
 - Digital Tools

Previous Attendee Profile

(Stats from Discovery Europe 2023)



Attended by these companies & many more:



WHO IS SPONSORING?

Drive Innovation & Accelerate Research

Gold Sponsors



Silver Sponsors

Ardigen



Bronze Sponsors



Network & Programme Sponsors



For sponsorship enquiries, please
contact sponsorship@oxfordglobal.com

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

Linked @OGConferences

Explore Curated & Insightful Content

Discovery Europe 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 100** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 22 May 2024

Track 1: Identification & Validation of Novel Targets

- New modalities & emerging drug targets in oncology, immuno-oncology and other disease areas
- AI to unblock drug discovery, drug repurposing and target validation
- Identification and validation of novel targets
- Discovery of 1st class inhibitors
- Induced proximity- RNA, Targeted RNA via small molecules
- Cellular and biological based drug discovery
- Digitisation & AI Approaches featured session

Track 2: Identification & Validation - Targeted Protein Degradation

- Targeted Protein Degradation And Target Validation
- Induced Proximity and Protein Degradation in Drug Discovery
- Novel Strategy to Induce the Degradation of a Target Protein
- Assay Technology Development & Tools

Track 3: Advanced Screening Approaches & Enabling Technologies

- Fast structure-based virtual screening in readily available chemical space
- Phenotypic screen in primary dendritic cells to identify new targets
- New technologies for target and phenotypic based discovery including spatial analysis
- Functional genomics approaches in drug discovery
- Target and Phenotypic Based Discovery including Functional Screening
- Affinity based Screening approaches
- Virtual Screening -Ligand vs structured based screening

Track 4: Advances In Medicinal Chemistry, Drug Design

- AI & Automation in chemical synthesis
- Efficient combination of machine learning and automation to accelerate DMTA cycles
- Measuring PK/PD and prediction of response AI in Chemical Synthesis
- Lead Optimisation
- Predicting PK/PD and predictive cellular modelling
- Exploring the Chemical space – effective search of the space- finding the best way
- Advances in Antibodies drug design
- Quantum Based Drug Design

Track 5: Therapeutic Strategies, Enabling Technologies & Biomarker Development

- Advancements and emerging trends in the application of technology in developing neurological treatments
- Neuroscience biomarker development
- Translational approaches for drug discovery
- Opportunities and challenges of designing and implementing targeted diagnostics and therapeutics
- The blood brain barrier in CNS diseases
- AI, digital and Imaging strategies for Biomarker development

Day Two | 23 May 2024

Track 1: Emerging Modalities of Drug Discovery- Targeted Protein Degradation

- Targeted Protein Degradation/ Molecular Glues
- Addressing Challenging Targets
- E3 Ligase Discovery

Track 1, Part 2: Animal Models for Disease, Organ Modelling - Organoid based Discovery & Organ On Chip development

- Animal Models for Disease
- Translating breakthrough discoveries in stem cell biology and organ development
- Utilisation of 3D-model systems and organoids in phenotypic and high content screening
- Modelling protein aggregation in human iPSC
- 3D media and 3D cell culture
- Safety and efficacy considerations
- Digitisation & AI Approaches featured session

Track 2: Molecular Drug Design & Hit Finding/ Optimisation

- Fragment & structured based drug discovery innovation including AI/ML driven approaches
- Innovating the chemistry lab bench
- Digitisation & AI Approaches featured session
- Showcase of hit-to-lead components & technologies e.g. targeted protein degradation, covalent inhibitors, DELs
- Case studies of lead generation in small and large molecules
- Enabling tools for hit-finding against difficult targets
- Applications of covalent fragments to drug lead generation
- Biophysical tools for difficult targets: building the right flow chart

Track 4: Drug Discovery for Neurodegenerative Diseases

- Target identification and validation approaches
- Neurodegenerative, and Neuroinflammation/ Immunology models for robust drug discovery
- Stem cell technology to fuel drug discovery
- iPSC cells for disease modelling and drug discovery
- In vitro and in vivo disease modelling
- Targeting and regulating neuroinflammation

Welcome

Attendees

Sponsors

▶ Session
Topic AreasProgramme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationOxford
Global
Plus PassForthcoming
Events

Book Now

Explore Curated & Insightful Content

Automate Europe 2024 features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 100** industry insights, sponsored presentations & think tank roundtable discussions.

Day One | 22 May 2024

Track 6: Bridging The Gap Between Automation & Digitalisation through FAIR & Digital Transformation

Part 1 – Lab Digitalisation via Automation, Lab Process Optimisation & Efficiency

- Building a digital and cost-effective lab (R&D, QC)
- Adoption of digital tools & technologies in labs
- Paperless labs, LIMS, ELNS integration
- Maximising system's efficiency in the lab:
 - » Developing softwares & hardwares for automated systems
 - » Lab analysis methods
 - » Cloud-based systems
- State-of-the art devices to integrate multiple lab techniques into a system: microfluidics – lab-on-a-chip

Part 2 – Data FAIRification

- FAIR data management in labs of the future
- Improving reproducibility
- Enhancing lab connectivity for streamlined FAIR data capture

Day Two | 23 May 2024

Track 4, Part 1: Data-Driven Modelling & Data Analytics for Drug Discovery & Development

- Building predictive & generative modelling
- Multi-modal data integration
- Quantum computing
- Leveraging Big Data

Track 7: Smart Manufacturing & Robotics

- Developing digital twins
- Implementation of a digital strategy
- Process control & optimization of manufacturing processes
- Hybrid modelling and in silico model development
- Deploying QbD and PAT from R&D to manufacturing processes
- Development of future mobile robotics in drug development
- Manufacturing, Production & Logistics of Mobile Robots
- Manufacturing of mobile robots
- Application of mobile robots in QA & QC environments
- Autonomous mobile robots in smart manufacturing

Track 4, Part 2: Automation with AI/ML & Robotics Tools in Drug Discovery & Development

- Lab robotics & tools for drug discovery workflows:
 - » Automated liquid handlers
 - » Microplate readers
 - » Data visualisation tools
- Implementing AI/ML in the lab
- Robotic process automation
- Maximizing R&D through cloud-based control and automation of scientific workflows
- Potency assays

Welcome

Attendees

Sponsors









 Session
Topic Areas
Programme
HighlightsConfirmed
SpeakersAgenda:
Day OneAgenda:
Day TwoVenue
InformationOxford
Global
Plus PassForthcoming
Events

Book Now

Connect with Industry Influencers

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

Presentation highlights for Discovery Europe 2024 & Automate Europe 2024 include.

 <p>JOHAN LUTHMAN, Executive Vice President of R&D, Lundbeck</p> <p>Day One</p> <p>08:50 The Landscape And Breakthrough In Neuroscience</p>	 <p>SANNE GLAD, Scientific Director, Amgen Research Copenhagen</p> <p>Day One</p> <p>11:10 E3 Ligase Novel Binder Identification And Their Use Across Various Platforms</p>	 <p>ANNA VULPETTI, Associate Director, Novartis</p> <p>Day Two</p> <p>13.50 Integration HIT Finding Approaches For Difficult/Novel Targets</p>	 <p>THIERRY PRONCE, Director, Quality & Digital Strategy for Analytical R&D, GSK</p> <p>Day Two</p> <p>09:00 Automation Of Method Process Development</p>
 <p>STEVEN DRIVER, Global Energy Leader, Sanofi</p> <p>Day One</p> <p>08:30 Maintaining Energy And Sustainability In The Manufacturing Environment</p>	 <p>GEORGE KARAGEORGIS, Senior Scientist - Data, Automation, Robotics, AstraZeneca</p> <p>Day One</p> <p>Implementation Of A Digital Strategy</p>	 <p>SANDRINE DESSOY, Innovation Advisor, GSK</p> <p>Day One</p> <p>13.10 Application Of Digital Twins In Vaccine Process Development & Manufacturing</p>	 <p>BIANCA BRENNER, Head of MES Projects, Bayer</p> <p>Day One</p> <p>14:30 Integration Of IPC Equipment Into MES To Enable Paperless Production</p>

Programme Highlights

Interactive Sessions

- ✓ Panel Discussion: Landscape of Drug Discovery And Impact of AI Biologics Discovery & Development: Facilitating Collaborations, Future Prospectives & Research Directions
- ✓ Workshop: Overcoming The Blood Brain Barrier In The Delivery Of Therapeutics
- ✓ Panel Discussion: Emerging Modalities & Overcoming Challenges
- ✓ Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now?

Key Presentations

- ✓ RNA-Targeted Small Molecule Drugs: The Next Frontier
- ✓ AI and Digital Biomarkers for Multiple Sclerosis
- ✓ Functional Genomic Tools For Elucidating Novel Targets
- ✓ Chaining Experiments And Enabling Automation Workflows In R&D Labs
- ✓ Advanced Manufacturing Technologies For Mobile Robots

Welcome

Attendees

Sponsors

Session Topic Areas

▶ Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

Gain Expertise from Thought Leaders

DAY ONE

GREG HOLLINGWORTH

Director, Chemistry and TPD/Proximity Initiative Co-Lead, Novartis

FLORENT SAMAIN

Principal Research Scientist II, AbbVie

JEFF MESSER

Director Analytics, GSK

JAMES OVERELL

Group Medical Director, Roche

DAVIDE GIANNI

Senior Director, AstraZeneca

SANNE GLAD

Scientific Director, Amgen Research Copenhagen

THOMAS ULLRICH

Director Medicinal Chemistry, Novartis

OLIVER HUCKE

Associate Director, Chemistry (CNS Diseases), Boehringer Ingelheim

GERGELY TÓTH

Chief Executive Officer & Chief Scientific Officer, Cantabio Pharmaceuticals

DIPTI THAKKAR

Vice President, Target Biology and Pharmacology, Hummingbird Bioscience

NILS HANSEN

Chief Executive Officer, Vipergen

BERENGERE DUMOTIER

Associate Director, Novartis

IRENE CHOI

Head of Drug Discovery, Verge Genomics

SLIM CHIHA

Co-Founder & Chief Executive Officer, PROSION Therapeutics

NATHALIE CARTIER-LACAVE

Senior Vice President Neurobiology, Askbio

TAKHAR KASUMOV

Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University

OLIVIER LOISELEUR

Senior Team Leader, Syngenta

ULRICH LÜCKING

Vice President, Head of Chemistry, FoRx Therapeutics AG

PAULINA KOLASINSKA-ZWIERZ

Principal Scientist, Alchemab Therapeutics

XIANG YI

Principal Scientist, Amgen

JONATHAN MASON

Senior Research Fellow, Nxera Pharma / Sosei Heptares

GEOFFREY KERCHNER

Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche

KERSTIN HOFER

Senior Scientist & Matrix Lead, Roche

URS LANGEN

Lab Head, Roche

EMMA DAVIES

Associate Director, Healx

JON LEA

Team Leader, GSK

ROBIN LÖVING

Chief Scientific Officer, Salipro Biotech

CARL POELKING

Associate Director, Astex

OLIVIER KITTEN

Founder and Chief Executive Officer, Affilogic

SHRUTHI BHARADWAJ

Head of R&D Insights & Analytics, Sanofi

STEVEN DRIVER

Global Energy Leader, Sanofi

NIKOLAOS PAPAKOSTAS

Associate Professor at the School of Mechanical and Materials Engineering in University College, Dublin

ELIAS HAGMANN

Senior Manager Data Science & Information Architecture, Molecular Partners AG

DOMENICO PALUMBERI

Digital Operations Leader, GSK

GEORGIOS MAVRAKIS

Senior Associate Scientist, Johnson & Johnson

GEORGE KARAGEORGIS

Senior Scientist - Data, Automation, Robotics, AstraZeneca

ALASTAIR FLORENCE

Professor & Director of the EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University Of Strathclyde

TOM KISSLING

pRED Lab Automation Partner, F. Hoffmann La Roche Ltd

BART VAN LOON

Lab Information & Automation Specialist, Merck

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

Gain Expertise from Thought Leaders

SANDRINE DESSOY
Innovation Advisor, GSK

CARL HELMUT-COULON
Head of Future Manufacturing Concepts, INVITE GmbH

JAMIE CLIFTON
Senior Scientist, Roche

BIANCA BRENNER
Head of MES Projects, Bayer

MARKUS HUNGENBACH
Program Manager MES Global Program, Bayer

RAUL V. RODRIGUEZ
Vice President, Woxsen University

DAY TWO

SIMONA COTESTA
Director Global Discovery Chemistry, Novartis

JANET BROWNLEES
Senior Director, Merck Sharpe and Dohme

GREGORI GEREBTZOFF
Director, Novartis

AMELIE JOFFRIN
Investigator & Associate Fellow, GSK

DANIEL SEELIGER
Head of Small Molecule Design, Exscientia

MORTEN GRUNNET
Vice President & Head of Neuroscience, Lundbeck

ARIANNA SABÒ
Head of R&D, Quantro Therapeutics GmbH

ROBERT FREMEAU
Chief Scientific Officer and Founder, BrainStorm Therapeutics

LUDOVIC COLLIN
Head of Neuroimmunology, Roche

JULIAN RÖWE
Senior Scientist, AbbVie

MARKUS SCHADE
Senior Scientist for NMR Fragment Screening, Astra Zeneca

FILIP ROUDNICKY
Senior Principal Scientist, Group Leader Cellular Engineering, Lead Discovery, Therapeutic Modalities, F. Hoffmann-La Roche

ANNA VULPETTI
Associate Director, Novartis

ZORAN RANKOVIC
Director, St Jude Children’s Research Hospital

ULRIKE KUNZEL
Associate Principal Scientist, Astra Zeneca

ERIC GOEDKEN
Senior Principal Scientist, AbbVie

XINXIN GAO
Principal Scientific Manager, Genentech

ADRIANA SAVOCA
Associate Director, Translational PKPD, AstraZeneca

JEAN-PHILIPPE ROCHER
Head of Discovery, Chemistry, Addex Therapeutics

GRAHAM DEMPSEY
Chief Scientific Officer, Quiver Bioscience

DAOHONG ZHOU
Professor and Director, Center for Innovative Drug Discovery, University of Texas Health San Antonio

PETER BRANDT
Head Of Chemistry, Beactica Therapeutics

BORISLAV DEJANOVIC
Director – Translational Sciences & External Innovation, Vigil Neuroscience

HAI RAO
Professor and Chair, Southern University of Science & Technology

HENRIK MÖBITZ
Associate Director, Novartis

DAVID BEARSS
Chief Executive Officer, Halia Therapeutics

RINALDO MONTALVÃO
Senior Chemoinformatician Machine Learning Data Scientist, Gain Therapeutics

GIOVANNI SPAGNOLLI
Chief Technology Officer, Sibylla Biotech

GEBHARD THOMA
Associate Director, Novartis

THIERRY PRONCE
Director, Quality & Digital Strategy for Analytical R&D, GSK

PATRIK KAGELID
Data Engineer, AstraZeneca

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

CONFIRMED SPEAKERS

Gain Expertise from Thought Leaders

CHUANG KEE ONG
Director, Data Product, GSK

VERA JOST
Principal Associate Scientist, F.Hoffmann-La Roche

GEORG WUITSCHIK
Principal Scientist, F.Hoffmann-La Roche

PAOLA FERRINI
High Throughput Automation Investigator, GSK

JULIE FOURNIER
Senior Scientist, GSK

FELIX STEMMER
Senior Scientist II, Novartis

PRANAV BENDE
Senior Robotics Engineer, National Institutes Of Health

DALVIN DEOL
Senior Scientist, Modelling and Automation, GSK

ASMITA AGRAWAL
Group Manager, Novo Nordisk

OLIVER DE PEYER
Automation Scientist, MeiraGTx

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One


Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now





DAY ONE							
08:30	Oxford Global Welcome Address						
DISCOVERY EUROPE 2024				AUTOMATE EUROPE 2024			
TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS		TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT		TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION		TRACK 7: SMART MANUFACTURING & ROBOTICS	
<p>Keynote Address: Synergies Of Screening Strategies To Improve Small Molecule Hits Identification Success</p> <ul style="list-style-type: none">The drug discovery toolbox has expanded considerably with the development of new affinity screening techniques. Each of these techniques has its strengths and liabilities. The presentation will discuss how to leverage two screening strategies through a study case		<p>Keynote Address: The Landscape And Breakthrough In Neuroscience</p>		<p>Keynote Address: Application Of Digital Twins In Vaccine Process Development & Manufacturing</p> <ul style="list-style-type: none">The talk focuses on the development and use of Digital Twins by GSK for the development and control of vaccines production process. Development strategy will be discussed, examples of digital twin will be presented for batch and continuous processes		<p>Keynote Address: Maintaining Energy And Sustainability In The Manufacturing Environment</p> <ul style="list-style-type: none">The presentation “Maintaining Energy and Sustainability in the Manufacturing Environment” shares Sanofi’s energy and environmental goals, program, and roadmap including process optimization. Maintaining a sustainable future combining AI with energy management systems is also reviewed. The second part of the presentation focuses on Sanofi’s recent continuous manufacturing facility	
FLORENT SAMAIN, Principal Research Scientist II, AbbVie		JOHAN LUTHMAN, Executive Vice President of R&D , Lundbeck		SANDRINE DESSOY, Innovation Advisor, GSK		STEVEN DRIVER, Global Energy Leader, Sanofi	
DISCOVERY EUROPE 2024				AUTOMATE EUROPE 2024			
TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS		TRACK 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	TRACK 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	TRACK 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	TRACK 7: SMART MANUFACTURING & ROBOTICS
Track Chair: <i>Position Available</i>		Track Chair: RICHARD LEWIS, Director Data Science, Novartis	Track Chair: <i>Position Available</i>	Track Chair: BARTOSZ BARANOWSKI, Senior Expert Data Science, Novartis	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>
<p>Track Keynote Address: Discovery And Validation Of ADC</p>		<p>Track Keynote Address: A Pro-Drug Strategy For Delivering Degraders To Achieve An Extended Duration Of Action</p>	<p>Track Keynote Address: Next Generation Antisense Oligonucleotide (ASO) Therapies To Address Challenging Or Previously Undruggable Targets Via Its LNAplus™ Platform</p>	<p>Track Keynote Address: AI/ML In Drug Discovery: DNA Encoded Libraries Use Case</p> <ul style="list-style-type: none">DNA Encoded Libraries (DELs) are invaluable in small molecule drug discovery, providing vast datasets efficiently. By properly leveraging this data, machine learning models can predict drug-target interactions, identify novel compounds, and optimize drug design. This integration accelerates drug discovery, leading to more efficient and targeted therapeutic interventions	<p>Track Keynote Address: Digital Biomarkers For Multiple Sclerosis</p> <ul style="list-style-type: none">Clinical digital biomarkers offer the opportunity to meaningfully reflect daily impairment in MS, and to measure that impairment accurately. Both passive and active measurements bring considerable challenges. Using a measure during a clinical development program requires clarity regarding its purpose, and judgement regarding its ability to meet that purpose	<p>Track Keynote Address: Data FAIRification And The Overall Digitalization Through Digital Transformation</p>	<p>Track Keynote Address: Advanced Manufacturing Technologies For Mobile Robots</p> <ul style="list-style-type: none">The potential of mobile collaborative robots for improving current manufacturing practices in personalised therapeuticsThe benefits and challenges of introducing robots in biologics are explored, including current practices, limitations, likely future practices, and the market outlookExperiments demonstrating the application of a mobile collaborative robot to perform three different routine tasks are presentedThe investigations highlight the potential of collaborative mobile robotic platforms for automating the routine tasks carried out within the biomufacturing sector <p>NIKOLAOS PAPAKOSTAS, Associate Professor, School of Mechanical and Materials Engineering, University College Dublin</p>
OLIVIER KITTEN, Founder and Chief Executive Officer, Affilogic		GREG HOLLINGWORTH, Director, Chemistry and TPD/Proximity Initiative Co-Lead, Novartis	ALEXANDER GEBAUER, Chief Executive Officer, Secarna Pharmaceuticals GmbH	JEFF MESSER, Director Analytics, GSK	JAMES OVERELL, Group Medical Director, Roche	SHRUTHI BHARADWAJ, Head of R&D Insights & Analytics, Sanofi	
Solution Provider Presentation		Platinum / Gold Solution Provider Presentation	De-Risked Hit Finding And Orthogonal Triaging Through Mass Spectrometry	Platinum / Gold Solution Provider Presentation	Platinum / Gold Solution Provider Presentation	Platinum / Gold Solution Provider Presentation	Gold Solution Provider Presentation
		<div>Reserved</div>	<ul style="list-style-type: none">Pivot Park Screening Centre (PPSC) incorporated Affinity Selection Mass Spectrometry (ASMS) into its high-throughput screening operations, enhancing the study of protein-ligand interactions. This label-free, high-throughput compatible method allows for efficient screening of large compound libraries without the need for mobilization or extensive assay development	<div>Reserved</div>	<div>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</div>	<div>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</div>	
Senior Representative, Causaly			SAMAN HONARNEJAD, Chief Scientific Officer, Pivot Park Screening Centre				Senior Representative, Omron
<div>causaly</div>			<div></div>				<div>omron</div>

BROCHURE CONTENTS

Welcome
Attendees
Sponsors
Session Topic Areas

Programme Highlights
Confirmed Speakers
Agenda: Day One
Agenda: Day Two
Venue Information
Oxford Global Plus Pass
Forthcoming Events

Book Now

	TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	TRACK 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	TRACK 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	TRACK 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	TRACK 7: SMART MANUFACTURING & ROBOTICS
09:50	MORNING BREAK		1-2-1 Meetings x4		Poster Displays		
11:10	Functional Genomic Tools For Elucidating Novel Targets <ul style="list-style-type: none"> Target selection is the first and most important decision we take in the drug discovery and development process. I will illustrate some of the key challenges and opportunities we have in Target Discovery in industry and how early adoption of a collaborative mind set, AI and machine learning and integrating genome editing and automation capabilities can help address them A couple of case studies will be presented to exemplify target discovery capabilities outside of just the Target Identification and Validation process <p>DAVIDE GIANNI, Senior Director, AstraZeneca</p>	E3 Ligase Novel Binder Identification And Their Use Across Various Platforms <p>SANNE GLAD, Scientific Director, Amgen Research Copenhagen</p>	From Phenotypic Screening To Target Identification - A Case Study <p>THOMAS ULLRICH, Director Medicinal Chemistry, Novartis</p>	Designing Drug-Like High Affinity Ligands For A TPP-Orthogonal Riboswitch <ul style="list-style-type: none"> Using structure-based design, a drug-like nanomolar affinity ligand for a riboswitch was obtained that modulates a redesigned switch rendered insensitive to its natural substrate TPP. Such systems could find applications in next-generation gene therapies <p>OLIVER HUCKE, Associate Director, Chemistry (CNS Diseases), Boehringer Ingelheim</p>	Identifying Pharmacological Chaperones As Disease Modifying Therapeutic Candidates For Alzheimer's And Parkinson's Disease <ul style="list-style-type: none"> Structure-biology basis of the interaction between small molecules and intrinsically disordered proteins introduced Identification of small molecule binders of intrinsically disordered proteins, such as α-synuclein and tau, using unique computational structure-based or biophysics based high-throughput screening approaches Application of pharmacological chaperones in Alzheimer's and Parkinson's disease <p>GERGELY TOTH, Chief Executive Officer & Chief Scientific Officer, Cantabio Pharmaceuticals</p>	Implementation Of A Digital Strategy <p>GEORGE KARAGEORGIS, Senior Scientist - Data, Automation, Robotics, AstraZeneca</p>	Automated Supply In Pharmaceutical Packaging Of The Future <ul style="list-style-type: none"> The current state of the art does not allow for the economical automation of material supply for secondary packaging ~20 pharmaceutical companies, packaging machine manufacturers and automation specialists therefore joined forces to develop a disruptively simpler solution concept The presentation presents the result and the planned implementation <p>CARL HELMUT-COULON, Head of Future Manufacturing Concepts, INVITE GmbH</p>
11:30	AI And ML In Drug Discovery – Empowering People And AI Models <ul style="list-style-type: none"> The FAIRification of data (making data findable, accessible, interoperable and reusable) has been an important goal in recent years. Now we will focus on how we can maximize the benefits and get the most out of the data. We will look at interfaces that empower both humans and AI. This will enable LLM-based AI assistants to programmatically interact with user-defined data sources and draw conclusions that lead to new insights <p>MANUEL STRITT, Head of Scientific Computing Drug Discovery, Idorsia Pharmaceuticals Ltd</p>	Molecular Glue, DELs And Protein Degradation <ul style="list-style-type: none"> DELs in Cells Multiplexing Molecular glue direct screen <p>NILS HANSEN, Chief Executive Officer, Vipergen</p>	High Throughput Cellular Assay Applications In Early Discovery <ul style="list-style-type: none"> Cellular target engagement technologies for membrane and soluble proteins High content biology applications to support hit to lead progression <p>JON LEA, Team Leader GSK</p>	Impact Of Secondary Pharmacology Data In Drug Discovery Phase: Alleviate The Risk Of Clinical Adverse Effects <p>BERENGERE DUMOTIER, Associate Director, Novartis</p>	Advancements In Gene Therapy Approaches For The Treatment Of CNS Diseases <p>NATHALIE CARTIER-LACAVE, Senior Vice President Neurobiology, Askbio</p>	Panel Discussion: Automation & Robotics In Drug Discovery & Development – Where Are We Now? <p>Moderator: GEORGIOS MAVRAKIS, Senior Associate Scientist, Johnson & Johnson Panellist: PAOLA FERRINI, High Throughput Automation Investigator, GSK NIKOLAOS PAPAKOSTAS, Associate Professor, School of Mechanical and Materials Engineering, University College Dublin</p>	Digital Transformation Of CMC: DataFactories And Digital Twins <ul style="list-style-type: none"> Overview of predictive toolbox development for crystallisation (CCS) and drug product (MCS+) Building the data fabric to support product and process development Data factories and automated workflows to accelerate development Challenges & opportunities for industrial digital technologies in CMC <p>ALASTAIR FLORENCE, Director, CMAC, University Of Strathclyde</p>
11:50	Solution Provider Presentation <p>Senior Representative, Pelago Bioscience</p> 	Silver & Above Solution Provider Presentation <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	Silver & Above Solution Provider Presentation <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	Solution Provider Presentation <p>Senior Representative, XtalPi</p> 	Solution Provider Presentation <p>Senior Representative, Sapient</p> 	Silver & Above Solution Provider Presentation <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	Solution Provider Presentation <p>Senior Representative, Essert Robotics</p> 
12:10	LUNCH BREAK		1-2-1 Meetings x3		Poster Displays		
	Track Chair: <i>Position Available</i>	Track Chair: GREG HOLLINGWORTH, Director, Chemistry and TPD/Proximity Initiative Co-Lead, Novartis	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>	Track Chair: <i>Position Available</i>

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

▶ Agenda: Day One










Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

	TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	TRACK 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	TRACK 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	TRACK 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	TRACK 7: SMART MANUFACTURING & ROBOTICS
13:10	<p>Unveiling Novel Targets Through The Lens Of Medicinal Chemistry</p> <ul style="list-style-type: none"> Disease relevance and druggability of novel targets rarely match. However, new drug mechanisms and modalities have challenged our current view on “undruggable targets”. We will discuss how to leverage on the right lead finding strategy to address also difficult targets with small molecules <p>IOLANDA MICCO, Head of Discovery Chemistry, Axxam</p> 	<p>Integrated Drug Discovery For Protein Degraders And Molecular Glues</p> <ul style="list-style-type: none"> Targeted protein degradation offers promise for previously undruggable targets. NUVISAN's integrated protein degradation platform accelerates degrader discovery with a) state-of-the-art PROTAC and glue profiling technologies, b) efficient synthesis (>100 degraders/ day) combined with direct-to-biology approaches, c) POI, E3 ligase and respective binder identification. This comprehensive solution supports the drug discovery efforts from binder finding all the way to clinical degrader candidates <p>YANSONG WANG, Scientist II Medicinal Chemistry, Nuvisan</p> 	<p>Solution Provider Presentation</p> <p>Senior Representative, Ardigen</p> 	<p>Predicting Pharmacokinetics From Limited ADME Data With Deep Learning</p> <ul style="list-style-type: none"> We present Cerella™, a unique deep-learning platform that can use limited ADME data to predict in vivo PK more accurately, focus resources and improve the chance of success, illustrated with case studies, including prospective project applications <p>MATTHEW SEGALL, Chief Executive Officer, Optibrium</p> 	<p>Solution Provider Presentation</p> <p>Senior Representative, Biognosys</p> 	<p>Bronze & Above Solution Provider Presentation</p> <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	<p>Bronze & Above Solution Provider Presentation</p> <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>
13:30	<p>Cryo-Electron Microscopy Is Revolutionizing Rational Drug Discovery Pipelines</p> <ul style="list-style-type: none"> Cryo-EM is a powerful technique for high-resolution analysis of drug-target interactions. This talk will cover several studies, including CDK-activating kinase, ion channels, and GPCRs, where cryo-EM was employed for structure-based drug design <p>IEVA DRULYTE, Senior Scientific Solutions Consultant, Thermo Fisher Scientific</p> 	<p>Bronze Solution Provider Presentation</p> <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	<p>High Throughput Screening Of The pH-Activated GPR65 And GPR68 Receptors</p> <ul style="list-style-type: none"> GPR65 & GPR68 are pH-activated receptors that have been implicated in cancer. EuroscreenFast has developed custom cell lines and assays for GPR65 & GPR68, and used these in a high-throughput screening campaign to identify a number of primary hits from a compound library. These can serve as potential starting points to develop drug candidates against each GPCR <p>LAURENT MEEUS, Chief Scientist & Business Unit Director, EuroscreenFast</p> 	<p>Bronze Solution Provider Presentation</p> <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	<p>Bronze Solution Provider Presentation</p> <p><i>For sponsorship opportunities please contact: sponsorship@oxfordglobal.com</i></p>	<p>Solution Provider Presentation</p> <p>Senior Representative, Chemspeed Technologies</p> 	<p>Solution Provider Presentation</p> <p>Senior Representative, Rapid Micro Biosystems</p> 
13:50	<p>Panel Discussion: Landscape Of Drug Discovery And Impact Of AI</p> <ul style="list-style-type: none"> Hype or Reality Demonstrating utility Discussion of when AI/ML fails Cultural shift & adoption <p>Moderator: JEFF MESSER, Director Analytics, GSK</p> <p>Panellist: GRAHAM DEMPSEY, Chief Scientific Officer, Quiver Bioscience</p> <p>DENISE BARRAULT, Director Novel Technology and Biology Partnerships, Exscientia</p> <p>DAVID BEARSS, Chief Executive Officer, Halia Therapeutics</p>	<p>Panel Discussion: Advances In CRISPR-Based Genome Editing For Target Identification And Validation</p> <ul style="list-style-type: none"> Leveraging AI in CRISPR Screening Base Editing Multiple Gene Knockouts Complex cell models Automation Endpoint multiplexing <p>Panellists: ULRIKE KUNZEL, Associate Principal Scientist, AstraZeneca</p>	<p>Panel Discussion: The Use Of Human Genetics Data For TITV</p> <ul style="list-style-type: none"> The opportunities of Human Genetics for Drug Discovery Examples of how this is working today Current gaps and what are we missing What does success look like and how we get there <p>Moderator: DAVIDE GIANNI, Senior Director, AstraZeneca</p>	<p>Panel Discussion: Accelerating DMTA Cycle</p> <ul style="list-style-type: none"> AI/ML Automation - Chemical Libraries etc Structured based Design Data Analysis & Integration <p>Moderator: GEORG RÜEDI, Senior Director, Chemistry Technologies, Idorsia</p> <p>Panellist: SIMONA COTESTA, Director Global Discovery Chemistry, Novartis</p> <p>GUIDO KOCH, Chief Executive Officer & Co-Founder, Amphilix AG</p> <p>VLADIMIR TALIBOV, Associate Principal Scientist, Sprint Bioscience AB</p>	<p>Panel Discussion: Translational Challenges In Neuro-Immunology</p> <ul style="list-style-type: none"> How to speed up development, but manage risk Immunotherapies for neuroinflammation & neurodegeneration Correlation, prediction, and surrogacy of biomarkers in neuroscience <p>Panellists: JAMES OVERELL, Group Medical Director, Roche</p> <p>JOHAN LUTHMAN, Executive Vice President of R&D, Lundbeck</p> <p>JANET BROWNLEES, Senior Director, Merck Sharpe and Dohme</p>	<p>Panel Discussion: Data As A Product</p> <ul style="list-style-type: none"> Automated data capture Interconnectivity & transparency Data Governance <p>Moderator: SHRUTHI BHARADWAJ, Head of R&D Insights & Analytics, Sanofi</p> <p>Panellists: REKHA LAKSHMANAN, Global Head Of Data Office, AstraZeneca</p>	<p>Panel Discussion: Navigating The Future Of Manufacturing: Insights On Smart Manufacturing And Industry 4.0</p> <p>Moderator: REKHA LAKSHMANAN, Global Head Of Data Office, AstraZeneca</p> <p>Panellists: DALVIN DEOL, Senior Scientist, Modelling And Automation, GSK</p> <p>STEVEN DRIVER, Global Energy Leader, Sanofi</p>

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One



Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

	<div>TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS</div> <div>Using AI Discovery Strategies For Rare Disease</div> <div><ul style="list-style-type: none">Healz is a techbio company that utilizes artificial intelligence to discover drugs, with a primary focus on uncovering treatments for rare diseases. This presentation will delve into our approach to drug discovery, shedding light on our advancements in pinpointing new mechanisms in rare diseases and potential new treatments</div> <div>EMMA DAVIES, Associate Director, Healx</div>	<div>TRACK 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION</div> <div>Advancing Lead Generation Strategies For Targeted Protein Degradation</div> <div><ul style="list-style-type: none">Lead generation examplesValidation and mechanistic studiesEvolution of turning hits into leads</div> <div>DIANA ZINDEL, Associate Director, AstraZeneca</div>	<div>TRACK 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES</div> <div>Enabling DEL For Membrane Proteins With The Salipro Platform: Screenings, Characterisation & cryoEM For Challenging Drug Targets</div> <div><ul style="list-style-type: none">Many membrane proteins represent emerging drug targets known to be notoriously difficult to work withThe Salipro DirectMX® technology incorporates membrane proteins directly from cell membranes into lipid Salipro® nanoparticles, presenting new opportunities for de novo development of biologics and small molecule drugsWe will present our latest developments showcasing DEL screening using native GPCRs and ion channels</div> <div>ROBIN LÖVING, Chief Scientific Officer, Salipro Biotech</div>	<div>TRACK 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN</div> <div>Redefining Druggability With ProMs – A Radically New Therapeutic Approach</div> <div><ul style="list-style-type: none">PROSION Therapeutics pioneered the first approach capable of disrupting the most common communication between disease-relevant proteins, making many well-known undruggable targets finally druggable</div> <div>SLIM CHIHA, Co-Founder & Chief Executive Officer, PROSION Therapeutics</div>	<div>TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT</div> <div>A Patient-First Approach To Discovery Of Antibodies Against Neurodegenerative Diseases</div> <div><ul style="list-style-type: none">Alchemab's goal is to use the power of human immune system to identify disease-relevant targets as well as antibodies which can fight complex diseases. By surveying B cell receptor repertoires of resilient subjects using Next Generation Sequencing, bioinformatics, proteomics and phage display, we identify antibodies and targets to validate in the disease setting. Our platform is deliberately target-agnostic and we apply this novel approach to find first-in-class treatments for neurodegenerative diseases and cancer</div> <div>PAULINA KOLASINSKA-ZWIERZ, Principal Scientist, Alchemab Therapeutics</div>	<div>TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION</div> <div>Building In House LIMS/ELN For Data Automation</div> <div>ELIAS HAGMANN, Senior Manager Data Science & Information Architecture, Molecular Partners AG</div>	<div>TRACK 7: SMART MANUFACTURING & ROBOTICS</div> <div>Necrobotics 360: Shaping The Future Of Healthcare</div> <div><ul style="list-style-type: none">Necrobotics pioneers a healthcare revolution, integrating AI and robotics to advance patient care and diagnostics. Precision in procedures, from diagnosis to surgery, is enhanced. Ethical concerns are addressed through stringent regulations. Collaborative efforts aim to shape a future where AI and robotics harmonize, reshaping healthcare for all</div> <div>RAUL V. RODRIGUEZ, Vice President, Woxsen University</div>
14:30							
14:50	<div><div>AFTERNOON BREAK</div><div>1-2-1 Meetings x3</div><div>Poster Displays</div></div>						
15:50	<div>Chemogenomic Screens For Target Identification</div> <div><ul style="list-style-type: none">This talk will focus on the application of GSK's chemogenomic (CxG) screening platform to enable target identification as a stand-alone approach or alongside genetic screening. We will describe our CxG capability and its application in disease-relevant primary cellular systems, such as iPSC derived macrophages</div> <div>AMELIE JOFFRIN, Investigator & Associate Fellow, GSK</div>	<div>Improved Hit Identification In Small Molecule Screening By Effective Counter- And Orthogonal-Assays</div> <div><ul style="list-style-type: none">High-throughput screening focusing solely on primary assays often struggles to generate high quality hits due to compound interference. Here we present case studies demonstrating how a catalytically inactive counter screen and a thermal shift orthogonal assay effectively triage false positives and expedite high-quality hit identification</div> <div>XIANG YI, Principal Scientist, Amgen</div>	<div>On Target Phenotypic And Virtual Based Screening</div> <div>OLIVIER LOISELEUR, Senior Team Leader, Syngenta</div>	<div>New Opportunities For The Utilization Of The Sulfoximine Group in Medicinal Chemistry From The Drug Designer's Perspective</div> <div><ul style="list-style-type: none">Interest in sulfoximines for medicinal chemistry has increased substantially in recent years. This presentation highlights emerging trends and opportunities for drug designers for the utilization of the versatile sulfoximine group, such as in the construction of complex molecules, proteolysis targeting chimeras (PROTACs), antibody–drug conjugates (ADCs) or cyclic peptides</div> <div>ULRICH LÜCKING, Vice President, Head of Chemistry, FoRx Therapeutics AG</div>	<div>Workshop: Overcoming The Blood Brain Barrier In The Delivery Of Therapeutics - Presentation 1: Therapeutic Strategies In Alzheimer's Disease</div> <div>GEOFFREY KERCHNER, Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche</div>	<div>Pioneering Digital Transformation In The Lab</div> <div>JAMIE CLIFTON, Senior Scientist, Roche</div>	<div>Integration Of IPC Equipment Into MES To Enable Paperless Production</div> <div><ul style="list-style-type: none">We share a project-approach for connecting IPC devices to a MES with the aim to automate processes and eliminate paper. Presentation will cover situation at a pharmaceutical company, challenges faced and highlight the decisions taken. You will get insights into approach, understand GxP considerations and benefit from a lessons learned.</div> <div>BIANCA BRENNER, Head of MES Projects, Bayer</div> <div>MARKUS HUNGENBACH, Program Manager MES Global Program, Bayer</div>
16:10	<div>Application of ML /AI In Discovery In Target ID To Clinical Proof Of Concept</div> <div><ul style="list-style-type: none">Introduction to CONVERGE, the Verge platform used to identify novel targetsVerge's journey in ALS with PIKfyve small molecule inhibitorFuture direction and expansion for AI/ML application beyond drug discovery</div> <div>IRENE CHOI, Head of Drug Discovery, Verge Genomics</div>	<div>Ethanol Impacts Hepatic Metabolism Via Altered Acetylation Dynamics In Mice</div> <div><ul style="list-style-type: none">Ethanol (EtOH) induces liver damage and alters metabolismThe acetylome dynamics method examined EtOH-induced hepatic injury in mice, revealing reduced turnover and elevated acetylation of mitochondrial proteins and histonesThese changes altered metabolism and induced oxidative stress</div> <div>TAKHAR KASUMOV, Associate Professor of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University</div>	<div>Leveraging AI For Arrayed CRISPR Screening For Target Identification</div> <div><ul style="list-style-type: none">We have developed an arrayed CRISPR screening platform for primary cell models. Embedding AI and machine learning approaches into that platform allows us to mine of knowledge graphs to generate hypotheses that can then be validated using CRISPR, as well as separate distinct phenotypes in CRISPR screens with imaging endpoints</div> <div>ULRIKE KUNZEL, Associate Principal Scientist, AstraZeneca</div>	<div>What CADD Approaches Are Really Impacting Drug Discovery?</div> <div><ul style="list-style-type: none">Prediction of binding, potency and selectivityKey role of water networks and lipophilic hotspotsHow to get FEP binding affinity prediction methods working well for GPCRsNew approaches for selectivityGetting the best from experimental structuresAI, AlphaFold2...</div> <div>JONATHAN MASON, Senior Research Fellow, Nxera Pharma / Sosei Heptares</div>	<div>Presentation 2: Diligent Design Of Brainshuttle-Antisense Oligonucleotide Conjugates For Brain Delivery</div> <div><ul style="list-style-type: none">Antisense-oligonucleotides are a promising drug modality for the treatment of neurological disorders, but their administration via IT is limiting their broader clinical application. Peripheral delivery of ASOs to the CNS by conjugation to a Brainshuttle™ antibody is investigated</div> <div>KERSTIN HOFER, Senior Scientist & Matrix Lead, Roche</div>	<div>Bridging The Gap Between Warehouse Data And Equipment Data</div> <div>BART VAN LOON, Lab Information & Automation Specialist, Merck</div>	<div>End To End (E2E) Automated For Drug Product And Device Testing</div> <div><ul style="list-style-type: none">This talk introduces an end-to-end automated laboratory solution that enables 24/7 drug product and medical device testing in a GMP-compliant mannerThe system leverages advanced robotics and software platforms to develop fully automated workflows to drive major efficiency gains and meet the evolving demands of an increasingly diverse product portfolio</div> <div>GEORGIOS MAVRAKIS, Senior Associate Scientist, Johnson & Johnson</div>

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

▶ Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

	TRACK 1: IDENTIFICATION & VALIDATION OF NOVEL TARGETS	TRACK 2: IDENTIFICATION & VALIDATION - TARGETED PROTEIN DEGRADATION	TRACK 3: ADVANCED SCREENING APPROACHES & ENABLING TECHNOLOGIES	TRACK 4: ADVANCES IN MEDICINAL CHEMISTRY, DRUG DESIGN	TRACK 5: THERAPEUTIC STRATEGIES, ENABLING TECHNOLOGIES & BIOMARKER DEVELOPMENT	TRACK 6: BRIDGING THE GAP BETWEEN AUTOMATION & DIGITALISATION THROUGH FAIR & DIGITAL TRANSFORMATION	TRACK 7: SMART MANUFACTURING & ROBOTICS
16:30	<div>Delegates welcome to attend co-located sessions</div>	<div>Delegates welcome to attend co-located sessions</div>	<div>Cell Engineering And CRISPR genetic Screening In Physiological Models</div> <div><ul style="list-style-type: none">Employing CRISPR/Cas9 in hPSCs, this talk examines AKT2's impact on endothelial dysfunction. It also presents a CLDN5 reporter for screening compounds that fortify endothelial cell barrier and details a nucleofection method in iPSC-derived immune cells to find lipid metabolism regulators</div> <div>FILIP ROUDNICKY, Senior Principal Scientist, Group Leader Cellular Engineering, Lead Discovery, Therapeutic Modalities, F. Hoffmann-La Roche</div>	<div>Scale Up Your Experts, Skill Up Your Data: Augmented Interactive Design In Fragment-Based Drug Discovery</div> <div><ul style="list-style-type: none">This talk will explore ideas around Augmented Interactive Design as a strategy that integrates AI-driven approaches with human expertise – thus adding scale to the tradition of carefully handcrafted design</div> <div>CARL POELKING, Associate Director, Astex</div>	<div>Presentation 3: Beyond the Shuttle: Advances In Brain Delivery Of Biologics For The Treatment Of Neurodegenerative Diseases</div> <div><ul style="list-style-type: none">Here, we present data on Roche's Brainshuttle™ technology, from in vitro studies that shed light on the cellular mechanisms of transcytosis, to enhanced brain exposure in animal models and humans. We further demonstrate the versatility of our Brainshuttle™ in transporting different drug modalities including antibodies and anti-sense oligonucleotides to the CNS with a broad and homogeneous biodistribution</div> <div>URS LANGEN, Lab Head, Roche</div>	<div>An E2E Perspective On Digital And PAT Capabilities In Drug Substance Manufacturing</div> <div><ul style="list-style-type: none">Digital StrategyPAT introduction (e.g., Raman, in-line protein concentration)Data generationData foundation + data architectureData utilization (data democratization, self-service analytics, advanced analytics, digital twin, ML/AI)Process automation & advanced process control</div> <div>RAQUEL DE PADUA FERNANDES SILVA, Senior Associate Scientist, Johnson & Johnson Innovative Medicine</div> <div>VALENTINE TUYISHIME, Digital & Technology Lead, Johnson & Johnson</div>	<div>Robotics In The R&D Laboratory, Introducing Smart Lab Facilities And Factories</div> <div>TOM KISSLING, pRED Lab Automation Partner, F. Hoffmann La Roche Ltd</div>
16:50	<div>Panel Discussion: Emerging Modalities & Overcoming Challenges</div> <div><ul style="list-style-type: none">Which target for which modalityWorking towards predictability and ease of implementation<ul style="list-style-type: none">» Small Molecules» Antibodies» Oligonucleotides» RNA» Targeted Protein Degradation</div> <div>Moderator: DIANA ZINDEL, Associate Director, AstraZeneca Panellists: ALEXANDER GEBAUER, Chief Executive Officer, Secarna Pharmaceuticals GmbH GIOVANNI SPAGNOLLI, Chief Technology Officer, Sibylla Biotech</div>	<div>Panel Discussion: Data Generation & Modelling for Drug Discovery</div> <div><div>How FAIR is public data?</div><ul style="list-style-type: none">How can Pharma share data for model building without sharing IP?Generating new therapeuticsLeveraging data sources with solid data foundations & model validationDisease models based on advanced knowledge graphs</div> <div>Moderator: RICHARD LEWIS, Director Data Science, Novartis Panellists: CHUANG KEE ONG, Director, Data Product, GSK</div>	<div>Precision Medicine & Transformational Technologies In Regenerative Medicine</div> <div><ul style="list-style-type: none">Transplantation remains a high-risk, high-cost procedureCombine cellular bioengineering, regenerative medicine and advanced therapeutics, to promote long-term stable immune quiescence and reduce complications</div> <div>PAUL ANTHONY KEOWN, Professor of Medicine & Director, Immune Sciences, The University of British Columbia</div>	<div>Using AI In Drug Design</div> <div>RINALDO MONTALVÃO, Senior Chemoinformatician Machine Learning Data Scientist, Gain Therapeutics</div>	<div>Panel Discussion: Challenges Of The Blood Brain Barrier In Neuroscience Drug Development</div> <div><ul style="list-style-type: none">BBB permeabilityStructural complexityTranslation of models into effective treatments</div> <div>Panellists: GEOFFREY KERCHNER, Vice President, Global Head of Early Development – Neuroscience & Rare Diseases, Roche KERSTIN HOFER, Senior Scientist & Matrix Lead, Roche URS LANGEN, Lab Head, Roche</div>	<div>Delegates welcome to attend co-located sessions</div>	<div>Panel Discussion: Overcoming The Challenges – Manufacturing The Next Generation Of Pharmaceutical Mobile Robots</div> <div><div>Maintaining quality control</div><ul style="list-style-type: none">Meeting regulatory requirements throughout the robotic manufacturing processFlexibility and scalabilityIntegrating robotic systems into existing manufacturing infrastructures</div> <div>Moderator: ANNE-SOPHIE VERSTRAETE, Senior Product Owner, GSK Panellists: NIKOLAOS PAPAKOSTAS, Associate Professor, University College Dublin CARL HELMUT-COULON, Head of Future Manufacturing Concepts, INVITE GmbH</div>
17:10	End of Day 1 & Speed Networking						

BROCHURE CONTENTS

- Welcome
- Attendees
- Sponsors
- Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

▶ Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY TWO

DISCOVERY EUROPE ROUNDTABLE DISCUSSIONS

Roundtable Discussion 1: Accelerate DMTA Cycle By Enabling Science Through Innovative Automation And Data Management Technologies
Moderator: DIANA ZINDEL, Associate Director, AstraZeneca

Roundtable Discussion 2: Integration of DEL For The Optimisation of HITS
Moderator: SANNE GLAD, Scientific Director, Amgen Research Copenhagen

Roundtable Discussion 3: Digital Biomarkers In Neuroscience Clinical Development
• Current context of use of digital biomarkers
• Regulatory path for digital biomarkers
• Can we speed up the development and implementation of digital biomarkers?
Moderator: JOSÉ LUIS MOLINUEVO, Vice President & Head of Experimental Medicine, Lundbeck

Roundtable Discussion 4: Neuroinflammation/Immunology Models For Robust Drug Discovery
Moderator: TAREK SAMAD, Senior Vice President, Global Head of Research, Corporate Patents & Trademarks, Lundbeck

AUTOMATE EUROPE ROUNDTABLE DISCUSSIONS

Roundtable Discussion 1: EU Research Project TraceBot: AI Enabled Built-In Verification And Audit Trail Generation
• Short video demonstration: Robot-systems copying self-awareness from humans in sterility testing
• You recognize if your cup of coffee slips through your fingers... even though no SOP tells you to check this
• Future robotic systems will have the same “built in” capability of verification and failure detection
• Discussion: Will this revolutionize the way we qualify automated systems?
Moderator: CARL HELMUT-COULON, Head of Future Manufacturing Concepts, INVITE GmbH

Roundtable Discussion 2: Assessing The Growing Need For Laboratory Automation To Accelerate Drug Discovery Processes With Industry 4.0
• Examining the key factors of innovation and speed for developing new drugs and therapies
• Exploring strategies for applying low-code development, digital representation, and automated workflows
• How will industry 4.0 accelerate lab automation and drive faster drug discovery?
Moderator: PRANAV BENDE, Senior Robotics Engineer, National Institutes of Health

TRACK 1: EMERGING MODALITIES: TARGETED PROTEIN DEGRADATION

Track Chair: MARKUS SCHADE, Principal Scientist, AstraZeneca

TRACK 2: MOLECULAR DRUG DESIGN & HIT FINDING/ OPTIMISATION

Track Chair: *Position Available*

TRACK 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

Track Chair: DAVID BEARSS, Chief Executive Officer, Halia Therapeutics

TRACK 4, PART 1: DATA-DRIVEN MODELLING & DATA ANALYTICS FOR DRUG DISCOVERY & DEVELOPMENT

Track Chair: *Position Available*

Track Keynote: A Novel Strategy To Induce The Degradation Of A Target Protein By Interfering With Its Folding Pathway

- Folding interference is a novel strategy to achieve the selective degradation of a target protein. The discovery of small molecules acting with such a mechanism is made possible by Sibylla's proprietary platform. New in vitro and in vivo results of folding interfering degraders targeting Cyclin D1 will be presented

GIOVANNI SPAGNOLLI, Chief Technology Officer, Sibylla Biotech

Track Keynote: Implementation Of Physics Based Insilico Tools To Drive Design

- The DMTA cycle (Design, Make, Test, Analyze) represents the iterative workflow to optimize hits towards clinical candidates. We discuss the design aspect of the DMTA cycle and illustrates an example from KRASG12C. We employed a QM-based workflow to predict ligand-strain and compute 3D-PSA, as an indicator of passive permeability

SIMONA COTESTA, Director Global Discovery Chemistry, Novartis

Track Keynote: Accelerating Target Discovery In Neuroscience

- Identification of the next generation of neurodegeneration drug discovery targets beyond aggregated proteins is a challenge in the field. In silico approaches to harness the array of omics datasets now available may have a key part to play in target identification. The talk will include examples of how MSD Neuroscience are using these approaches

JANET BROWNLEES, Senior Director, Merck Sharpe and Dohme

Track Keynote: AI Chatbots & Biology: Generative AI And Knowledge Graphs For Frictionless Information Access

- Join us for an engaging session where we delve into the transformative power of SEND (Standard for Exchange of Nonclinical Data), knowledge graph databases, LLMs, and advanced computational techniques in enhancing data discoverability and utility

PATRIK KAGELID, Data Engineer, AstraZeneca

Predicting ADME/PK Properties For Targeted Protein Degraders

- Most TPDs fall outside of Lipinski's rule of five, raising the question of the applicability of traditional in silico ADME/PK models. We will address the performance of existing models on TPDs, and how to best leverage small TPD ADME/PK datasets

GREGORI GEREBTZOFF, Director, Novartis

Toward Automation Of Molecular Optimization

- Exscientia's mission is to encode and automate drug discovery. Humans are great at formulating problems but computers are inherently better positioned to solve complex optimization problems in high-dimensional search spaces. We present our approach of encoding molecular design using generative design, cheminformatics, biophysics as well as active learning

DANIEL SEELIGER, Head of Small Molecule Design, Exscientia

Translational Tools For Predictability In Neuroscience Diseases

- Predictive validity of animal models within neuroscience
- Correlating exposure to efficacy and adverse events (PK/PD)
- Reproducibility of preclinical studies

MORTEN GRUNNET, Vice President & Head of Neuroscience, Lundbeck

FAIR Data In The Pharmaceutical Industry

CHUANG KEE ONG, Director, Data Product, GSK

Gold/Platinum Solution Provider Presentation

For sponsorship opportunities
please contact:
sponsorship@oxfordglobal.com

Gold/Platinum Solution Provider Presentation

Reserved

Solution Provider Presentation

Senior Representative,
Bit.bio



Gold/Platinum Solution Provider Presentation

For sponsorship opportunities
please contact:
sponsorship@oxfordglobal.com

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

▶ Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

13:00

LUNCH BREAK



1-2-1 Meetings x3



Poster Displays

14:00

TRACK 1: EMERGING MODALITIES: TARGETED PROTEIN DEGRADATION

Development Of Potent And Selective Disulfide Constrained Peptide Binders Against The E3 Ubiquitin Ligase ZNRF3

XINXIN GAO, Principal Scientific Manager, **Genentech**

TRACK 2: MOLECULAR DRUG DESIGN & HIT FINDING/ OPTIMISATION

Discovery Of In Vivo Active, Small-Molecule IL17A Antagonists With Efficacy Equivalent To Anti-IL17

- Dysregulation of IL17A drives numerous inflammatory disorders with anti-IL17A inhibition proven as an effective treatment
- Oral anti-IL17 therapies are an attractive alternative option
- I will discuss discovery of novel small molecule IL17A inhibitors, identified via a DNA-encoded library screen and their optimization to in vivo efficacious inhibitors

ERIC GOEDKEN, Senior Principal Scientist, **AbbVie**

TRACK 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

Workshop: Emerging Modalities For Neurodegeneration - Presentation 1: Cellomics Platform Using Patient-Derived iPSC-Neurons-Based Screenings For Drug Discovery

- Automated cell culture system coupled to an automated imaging
- Rapid neuronal differentiation protocol using Neurogenin-2 (NGN2) and small molecule based neural precursor cells
- FDA-approved (n=1430) compound repurposing screening strategy for therapeutic discovery
- Arrayed large scale CRISPR-activation screening in iPSC-neuron

ASHUTOSH DHINGRA, Staff Scientist, **German Center for Neurodegenerative Diseases**

TRACK 4, PART 2: AUTOMATION WITH AI/ML & ROBOTICS TOOLS IN DRUG DISCOVERY & DEVELOPMENT

End To End (E2E) Automation Of Analytical Workflows

- In this presentation we will show how we connected and interfaced between Imprivata, Genedata Biologics, Chromeleon CDS, Liquid Handling Systems and an ELN to develop end to end automation of analytical workflows

FELIX STEMMER, Senior Scientist II, **Novartis**

14:20

DT2216, A BCL-XL Selective Degradar: From Laboratory To The Clinic

DAOHONG ZHOU, Professor and Director, **Center for Innovative Drug Discovery, University of Texas Health San Antonio**

Discovery Approaches In The mGlu Allosteric Modulators Field Both On Early Discovery Up To Clinical Development

- Allosteric modulators of mGluR1-8 have been shown to offer an attractive strategy to develop small molecule therapeutics that readily cross the blood-brain barrier
- We report our historical contribution with an highlight on technologies which enabled the discovery and the development of novel ligands and innovative drug candidates

JEAN-PHILIPPE ROCHER, Head of Discovery, Chemistry, **Addex Therapeutics**

Presentation 2: Specific Neuronal Subtypes And Co-Cultures From hiPSC For Modelling Neurodegeneration

JULIAN RÖWE, Senior Scientist, **AbbVie**

Direct To Biology Application

JULIE FOURNIER, Senior Scientist, **GSK**

14:40

TRACK 1, PART 2: ANIMAL MODELS FOR DISEASE, ORGAN MODELLING - ORGANOID BASED DISCOVERY & ORGAN ON CHIP DEVELOPMENT

Integrating In Vitro Data Into Mechanistic Modelling For Prediction And Interpretation Of PKPD And Anti-Tumour Activity Of Irreversible TKIs

- PKPD modelling can establish a link between compound concentrations, pharmacodynamic effect, and anti-tumour activity to support decision-making
- A case study on building a model integrating different types of in vitro data for irreversible TKIs is presented, focusing on target engagement requirements for FIH dose selection and interpretation of clinical data

ADRIANA SAVOCA, Associate Director, Translational PKPD, **AstraZeneca**

TRACK 2: MOLECULAR DRUG DESIGN & HIT FINDING/ OPTIMISATION

Solving Centuries-Old Drug Discovery Challenges With Artificial Intelligence: Hope Vs Hype

- Cost-effectiveness and improving efficacy/ safety in case of novel drugs
- Global multifaceted collaborations
- CADD combined with mathematical modelling is a magic bullet
- AI-based model has a lot of potential to revolutionize drug R&D
- Hybrid CADD- and AI- powered technology in case of novel predictive medicine

PRASHANT GAHTORI, Professor, **Graphic Era Hill University**

TRACK 3: DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

(Cont.) Workshop: Emerging Modalities For Neurodegeneration

Panel Discussion: Bringing Therapeutics To New Frontiers

- Case studies
- Implementation within the clinic
- New modalities in CNS disease

Panellists:
ROBERTO VILLASEÑOR SOLORIO, Principal Scientist, Lab Head Brain Delivery, Neuroscience and Rare Diseases, **Roche**
MORTEN GRUNNET, Vice President & Head of Neuroscience, **Lundbeck**
KERSTIN HOFER, Senior Scientist & Matrix Lead, **Roche**

TRACK 4, PART 2: AUTOMATION WITH AI/ML & ROBOTICS TOOLS IN DRUG DISCOVERY & DEVELOPMENT

RoSL: An HTE-Workflow At Roche – Built From The Ground Up

- High-Throughput Experimentation built for chemists with a focus on data flow and analysis

VERA JOST, Principal Associate Scientist & GEORG WUITSCHIK, Principal Scientist, **F.Hoffmann-La Roche**

15:00

Brain Organoids In Therapeutic Development

ROBERT FREMEAUX, Chief Scientific Officer and Founder, **BrainStorm Therapeutics**

Delegates welcome to attend co-located sessions

Panellists:
ROBERTO VILLASEÑOR SOLORIO, Principal Scientist, Lab Head Brain Delivery, Neuroscience and Rare Diseases, **Roche**
MORTEN GRUNNET, Vice President & Head of Neuroscience, **Lundbeck**
KERSTIN HOFER, Senior Scientist & Matrix Lead, **Roche**

Laboratory Automation Of Specialised Techniques In An AAV Research Pipeline

OLIVER DE PEYER, Director, Automation Scientist, **MeiraGTx**

15:20

Emerging Genome Editing Technologies For Developing Animal Models

- Genetically engineered animal models are widely used in drug discovery research. The CRISPR tool has simplified the process of generating such models and our lab has previously developed methods like Easi-CRISPR (Efficient additions with ssDNA inserts CRISPR) and GONAD (Genome editing via Oviductal Nucleic Acids Delivery) that are now widely adapted in the field. However, there are no robust technologies available for creating humanized animal models containing large sized gene fragments. Many drug discovery research projects rely on such large sized gene knock-in models. In this session I will present a few emerging technologies for designing and generating custom animal models useful for drug discovery research

CHANNABASAVIAH GURUMURTHY, Professor and Director, **University of Nebraska Medical Center**

Delegates welcome to attend co-located sessions

Unlocking The Potential Of TREM2: VG-3927 As A Novel Therapeutic For Alzheimer's Disease

- Hypofunction of the microglial TREM2 receptor increases the risk of Alzheimer's disease. We show that the small molecule TREM2 agonist VG-3927 is capable of favorably modulating microglia activation and instructing a broadly neuroprotective profile across preclinical model systems

BORISLAV DEJANOVIC, Director – Translational Sciences & External Innovation, **Vigil Neuroscience**

Automating Chemistry With Custom Robotics

PRANAV BENDE, Senior Robotics Engineer, **National Institutes Of Health**

15:40

End of Congress

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session Topic Areas

Programme Highlights

Confirmed Speakers

Agenda: Day One

▶ Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

Be Part of Something Exceptional



Messepl. 25, 4058
Basel, Switzerland

Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate:

Tuesday 21st May 2024 – £230, breakfast included

Wednesday 22nd May 2024 – £230, breakfast included

*Please note: £30 supplement is applicable for double occupancy

Should you wish to book a room, please email help@oxfordglobal.com. The final cut-off date to book bedrooms is Friday 3rd May 2024 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to cancellation charges.

<https://oxfordglobal.com/discovery/events/discovery-europe-2024#venue>



Please [click here to visit the hotel's website](#) &
recieve more information



Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

▶ Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

LinkedIn

@OGConferences

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!



Welcome to the future of life sciences engagement!

Effortless On-Demand Presentations

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

Beneficial Partnerships and Accelerated Learning

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic in-person and online events that drive professional growth.

Year-Round Exclusive Insights

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Elevate Your Event Experience

Event PLUS Pass includes catered lunches, ensuring you stay fuelled for vibrant discussions. You can also take the spotlight by showcasing your research projects through our eye-catching poster displays in the exhibition area – a prime opportunity for community engagement and invaluable feedback!

Your Passport to Unparalleled Access

Enjoy guaranteed entry to any Oxford Global event and online activities across all our brands. The PLUS Pass opens doors to a world of knowledge, connections, and opportunities for your continued success.

Full access across
all our Brands:

 **BIOLOGICS**

 **BIOMARKERS**

 **CELL & GENE**

 **DISCOVERY**

 **FORMULATION
& DELIVERY**

 **IMMUNO**

 **OMICS**

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

£499^{+VAT}

\$700^{+VAT}

Register Now 

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com

*Please note: PLUS Passes are unavailable to service and
solution providers/vendor companies

Linked 

 @OGConferences 

DISCOVERY SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.



Organ Modelling & 3D Cell Culture 2024

18 - 19 March 2024 London, UK

Discovery Europe 2024

22 - 23 May 2024
Basel, Switzerland

Automate 2024

22 - 23 May 2024
Basel, Switzerland

Advanced Screening Approaches for Drug Target Identification & Validation: Online Symposium

23 October 2024 | GMT (UTC+0)

Discovery US 2024

November 2024
Boston, USA



Biologics Series

Proteins & Antibodies | Peptides | Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Biomarkers Series

Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series

Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets &
Cell Types in Immuno-Oncology

Omics Series

Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/
to explore our diverse portfolio of events
across 2024.

Welcome

Attendees

Sponsors

Session
Topic Areas

Programme
Highlights

Confirmed
Speakers

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

► Forthcoming
Events

Book Now

OXFORD
GLOBAL
PLUS

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Oxford Global PLUS Pass includes
unrestricted access to all events
shown above and much more

Register Now

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com

LinkedIn

@OGConferences